Instrument Inactif

Communiqués Esperion Therapeutics, Inc.

Actions

ESPR

US29664W1053

Produits pharmaceutiques

Communiqués

17/06	Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR	BU
26/05	Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026	GL
14/05	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	GL
13/05	Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026	GL
04/05	Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR	BU
01/05	Esperion to be Acquired by ARCHIMED	GL
23/04	Esperion to Report First Quarter 2026 Financial Results on May 7	GL
02/04	Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics	AQ
02/04	Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)	GL
31/03	Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference	GL
30/03	Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026	GL
30/03	Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026	AQ
17/03	Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session	GL
16/03	Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia	GL
10/03	Esperion Therapeutics: Q4 Earnings Snapshot	AQ
10/03	Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	GL
10/03	Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	AQ
05/03	/C O R R E C T I O N -- HLS Therapeutics Inc./	AQ
04/03	Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst	AQ
03/03	Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)	BU
03/03	Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)	GL
24/02	Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10	GL
18/02	Esperion to Participate in The 2026 Citizens Life Sciences Conference	GL
18/02	Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL and NEXLIZET Prior to April 19, 2040	AQ
17/02	Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040	GL